💨 Abstract

Avadel Pharmaceuticals reported a $9.7 million net income for the second quarter of 2025, a significant improvement from the year-earlier period when it reported a loss. The Dublin-based company generated 10 cents in earnings per share, far surpassing the 2 cents predicted. It posted $68.1 million in revenue, exceeding forecasts of $61.8 million.

Courtesy: WTOP Staff